

Neoadjuvant chemotherapy regimens

Patients received an anthracycline- based and paclitaxel-based 8-cycle regimen of chemotherapy. Patients who were human epidermal growth factor receptor 2 (Her-2) positive received anti-Her-2 targeted therapy. Anthracyclines included adriamycin (60 mg/m² every 3 weeks for 4 cycles) and epirubicin (90 mg/m² every 2 weeks for 4 cycles). Paclitaxel includes doxorubicin (90 mg/m² every 3 weeks for 4 cycles) and abraxane (125 mg/m², d1, d8, d15 every 3 weeks for the next 4 cycles). For Her-2 positive patients, trastuzumab was accompanied by paclitaxel at a loading dose of 8 mg/kg, followed by a maintenance dose of 6 mg/kg.